Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Suspended 1Recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Lymphoma, T-Cell 5Recurrence 2Lymphoma, T-Cell, Peripheral 2Lymphoma 2Immunoblastic Lymphadenopathy 2Sezary Syndrome 1Mycosis Fungoides 1Lymphoma, Large-Cell, Anaplastic 1Leukemia, Prolymphocytic, T-Cell 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, Large Granular Lymphocytic 1Enteropathy-Associated T-Cell Lymphoma 1

Interventions

Cyclophosphamide 5Etoposide 3duvelisib 2Vincristine 2Prednisone 2Melphalan 2Doxorubicin 2Azacitidine 210-propargyl-10-deazaaminopterin 2tazemetostat 1sodium-iodide symporter 1ruxolitinib 1pembrolizumab 1fludarabine phosphate 1fludarabine 1etoposide phosphate 1cemiplimab 1belinostat 1X-Rays 1Whole-Body Irradiation 1Tacrolimus 1Specimen Handling 1Sirolimus 1Prednisolone 1Photons 1Peripheral Blood Stem Cell Transplantation 1Nivolumab 1Mycophenolic Acid 1Methotrexate 1Magnetic Resonance Spectroscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Immunoblastic Lymphadenopathy × duvelisib × 90 days × Clear all
NCT04803201 2026-06-02

Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma

Alliance for Clinical Trials in Oncology

Phase 2 Suspended
170 enrolled
Lymphoid

Immunoblastic Lymphadenopathy, Lymphoma, T-Cell, Enteropathy-Associated T-Cell Lymphoma

NCT06522737 2026-04-06

TERZO

SecuraBio

Phase 3 Recruiting
124 enrolled
Lymphoid

Immunoblastic Lymphadenopathy, Lymphoma, Recurrence, Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡